MedTrace Logo

The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

NCT01914211 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-02-01

No results posted yet for this study

Summary

This is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.

Conditions

  • Congenital Heart Disease

Interventions

DRUG

Tranexamic Acid

100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.

PROCEDURE

Acute Normovolemic Hemodilution

Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)

Sponsors & Collaborators

  • Aymen N Naguib

    lead OTHER

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01914211 on ClinicalTrials.gov